CJC-1295 + GHRP-2 dosage chart

10 mg Blend

The CJC-1295 + GHRP-2 peptide blend is dosed at 150 mcg–300 mcg daily via subcutaneous injection in educational protocols. A 10 mg blend reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration (1 unit ≈ 33.3 mcg).
Typical daily range: 100–300 mcg once daily (gradual titration).
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F) for long-term; after reconstitution, refrigerate and use within 2–4 weeks.
Injection frequency: Once daily — 5 days on, 2 days off (dose Mon–Fri, rest Sat–Sun).
Dosing schedule: 5 days on / 2 days off: dose Monday through Friday, then take Saturday and Sunday off. That is 5 dosing days per week.

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

WEEK	DAILY DOSE (MCG)	UNITS (PER INJECTION) (ML)
Weeks 1–2	150 mcg (0.15 mg)	4.5 units (0.045 mL)
Weeks 3–12	300 mcg (0.30 mg)	9 units (0.09 mL)

Advanced / Twice-Daily Approach (3 mL = ~3.33 mg/mL)

WEEK	DOSE PER INJECTION (MCG)	UNITS (PER INJECTION) (ML)	TOTAL DAILY (MCG)
Weeks 1–2	100 mcg (0.10 mg)	3 units (0.03 mL)	200 mcg
Weeks 3–12	150 mcg (0.15 mg)	4.5 units (0.045 mL)	300 mcg

Reconstitution steps

1Draw 3.0 mL bacteriostatic water with a sterile syringe.
2Inject slowly down the vial wall; avoid foaming.
3Gently swirl/roll until dissolved (do not shake).
4Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Dosing Cycle & Timing

This protocol runs on a 5 days on / 2 days off cycle.

Cycle: 5 days on, 2 days off — dose Monday through Friday and rest on the weekend.
5 dosing days per week; the 2 off days help limit receptor desensitisation and give injection sites time to recover.
Keep the dose time consistent on dosing days.
If a weekday dose is missed, take it the same day if possible — do not dose on an off day to catch up.
Weekly totals in the supplies and shopping lists are calculated on 5 dosing days, not 7.

Protocol Overview

Concise summary of the once-daily regimen.

Goal: Support enhanced GH pulsatility and sustained IGF-1 elevation over a defined research period.
Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
Dose Range: 100–300 mcg daily (total blend) with gradual titration.
Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
Storage: Lyophilized refrigerated or frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosing Protocol

Suggested daily titration approach.

Start: 100–150 mcg daily for Weeks 1–2 to allow acclimatization.
Target: 250–300 mcg daily by Weeks 3–12.
Frequency: Once per day (subcutaneous), preferably evening/bedtime.
Cycle Length: 8–12 weeks; optional extension to 16 weeks.
Timing: Inject on an empty stomach; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality.

Lyophilized: Refrigerate at 2–8 °C (35.6–46.4 °F); freeze at −20 °C (−4 °F) for long-term storage exceeding several months.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 2–4 weeks for optimal potency.
Allow vials to reach room temperature before opening to reduce condensation uptake.
If longer storage of reconstituted solution is needed, aliquot into sterile containers and freeze once; avoid repeated freeze–thaw.

Important Notes

Practical considerations for consistency and safety.

Use new sterile insulin syringes for each injection; dispose in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
Inject slowly on an empty stomach; GHRP-2’s GH response may be blunted by elevated blood glucose.
Document daily dose and site rotation to maintain consistency.
No post-cycle therapy is required; GH and IGF-1 levels return to baseline after cessation.

How This Works

CJC-1295 is a tetrasubstituted GHRH(1–29) analog engineered for extended half-life (~6–8 days) via protection from enzymatic degradation and reversible albumin binding. A single dose can sustain elevated GH for approximately 6 days and IGF-1 elevation for 9–11 days. GHRP-2 is a synthetic hexapeptide ghrelin-mimetic that binds the GH secretagogue receptor (GHS-R1a), triggering acute GH pulses that peak within ~25 minutes. Human research shows that GHRH and growth hormone-releasing peptide pathways can stimulate GH release synergistically. This supports the pathway rationale, while the exact compounds and route in the cited study differ from this blend.

Potential Benefits & Side Effects

Observations from preclinical and clinical literature.

Sustained elevation of GH and IGF-1 levels over extended periods with once-daily or even less frequent dosing.
Long-term pediatric studies (8 months) reported no significant adverse effects or toxicities from GHRP-2 therapy.
GHRP-2 may transiently increase appetite due to ghrelin-like activity.
Mild, transient elevations in ACTH, cortisol, and prolactin may occur shortly after injection but remain within physiological ranges.
CJC-1295 at higher doses may cause transient vasodilatory effects such as facial flushing or brief lightheadedness.
Occasional mild injection-site reactions (redness, itching) may occur with subcutaneous administration.

Lifestyle Factors

Complementary strategies for best outcomes.

Pair with a balanced, protein-forward diet tailored to energy and recovery needs.
Combine resistance training and aerobic activity to complement GH-mediated anabolic and metabolic effects.
Prioritize quality sleep; nocturnal GH secretion is enhanced by adequate rest.
Inject on an empty stomach or after fasting for 2–3 hours; carbohydrate-rich meals may attenuate GHRP-2’s GH response.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

Clean the vial stopper and skin with alcohol; allow to dry.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
Do not aspirate for subcutaneous injections; inject slowly and steadily.
Rotate sites systematically (abdomen, thighs, upper arms) to avoid local tissue changes.
Withdraw the needle at the same angle; dispose immediately in a sharps container.

Important Note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

Supplies needed

Plan covers the full 12-week protocol at the lowest listed starting dose: 0.15 mg per dose, 5 days on / 2 days off (60 administrations in total), using 10 mg vials. After mixing with 3 mL, the concentration is 3.33 mg/mL and each dose requires 0.05 mL total.

CJC-1295 + GHRP-2 vials (10 mg Blend each)

Vials are rounded up only after calculating the whole protocol: ceil(9 ÷ 10) = 1. Usable peptide remaining in an opened vial carries forward to the next dose.

Full protocol (12 weeks): 1 vial (9 mg needed ÷ 10 mg)

Insulin syringes (U-100, 1 mL)

One fresh syringe per administration.

Full protocol (12 weeks): 60 syringes

Bacteriostatic water (10 mL bottles)

Use 3 mL per vial for reconstitution (1 × 3 mL = 3 mL).

Full protocol (12 weeks): 1 × 10 mL bottle

Alcohol swabs

One for the vial stopper per draw + one for each injection site (5 days on / 2 days off). Recommend 2 × 100-count boxes.

Full protocol (12 weeks): 120 swabs

Supply	Full protocol (12 weeks)
CJC-1295 + GHRP-2 vials (10 mg Blend each)Vials are rounded up only after calculating the whole protocol: ceil(9 ÷ 10) = 1. Usable peptide remaining in an opened vial carries forward to the next dose.	1 vial (9 mg needed ÷ 10 mg)
Insulin syringes (U-100, 1 mL)One fresh syringe per administration.	60 syringes
Bacteriostatic water (10 mL bottles)Use 3 mL per vial for reconstitution (1 × 3 mL = 3 mL).	1 × 10 mL bottle
Alcohol swabsOne for the vial stopper per draw + one for each injection site (5 days on / 2 days off). Recommend 2 × 100-count boxes.	120 swabs

CJC-1295 + GHRP-2 dosage FAQs

How much bacteriostatic water do you use to reconstitute CJC-1295 + GHRP-2?

Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration (1 unit ≈ 33.3 mcg). for a 10 mg Blend vial. Add the water slowly against the inside wall of the vial and swirl — never shake — until the powder fully dissolves.

How often is CJC-1295 + GHRP-2 administered in research protocols?

Injection frequency: Once daily — 5 days on, 2 days off (dose Mon–Fri, rest Sat–Sun).

What does the CJC-1295 + GHRP-2 standard / gradual approach (3 ml = ~3.33 mg/ml) look like?

Weeks 1–2 — 150 mcg (0.15 mg) — 4.5 units (0.045 mL); Weeks 3–12 — 300 mcg (0.30 mg) — 9 units (0.09 mL). The full table above lists every step with matching syringe units.

What are the mixing steps for CJC-1295 + GHRP-2?

Draw 3.0 mL bacteriostatic water with a sterile syringe. Inject slowly down the vial wall; avoid foaming. Gently swirl/roll until dissolved (do not shake).

How should reconstituted CJC-1295 + GHRP-2 be stored?

Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F) for long-term; after reconstitution, refrigerate and use within 2–4 weeks..

How many insulin syringe units equal a CJC-1295 + GHRP-2 dose?

Units depend on the water volume you used. Divide your target dose by the vial concentration to get millilitres, then multiply by 100 — 1 unit on a U-100 insulin syringe is 0.01 mL. The Spartan Peptides reconstitution calculator does this conversion for you.

Is CJC-1295 + GHRP-2 approved for human use?

No. CJC-1295 + GHRP-2 is sold and referenced strictly as a research chemical. Nothing on this page is medical advice and the material is not for human consumption.

Educational and research information only. Not medical advice, not for human consumption. Values are reference figures — always verify your own math with the reconstitution calculator.

On any insulin syringe, 1 unit = 0.01 mL, so unit counts above hold across brands.